12/14/2020, 11:58 AM (Source: TeleTrader)
more TeleTrader news

CureVac starts late-stage trials of COVID vaccine

CureVac announced on Monday that it launched a late-stage trial of its coronavirus vaccine candidate.

The company noted the Phase 2b/3 trial will involve over 35,000 participants and will seek to assess the safety and efficacy of the vaccine.

"The clinical safety and immunogenicity data achieved to date look promising and we are hopeful that this trial will continue to demonstrate the impact of mRNA technology and our vaccine to prevent COVID-19, and to help defeat this pandemic," CureVac CEO Franz-Werner Haas stated.

Baha Breaking the News (BBN) / NP